linjc16/ctgov huggingface dataset:
Therapeutic Research in Multiple Myeloma

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to learn how myeloma cells grow and become a cancer, how to distinguish them from normal cells and how to eliminate these cells selectively.

Detailed Description
-----------------
Participating in this study will require that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of your multiple myeloma. Bone marrow/peripheral blood/tissue samples will be collected for research purposes, as well as testing for genetic traits of Castleman's disease if you consent to this study. In addition, data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.

Official Title
-----------------
UARK 91-004 Therapeutic Research in Multiple Myeloma

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Other: No drugs are involved


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Any subject evaluated for a MIRT protocol Exclusion Criteria: Subjects who have not been evaluated for a MIRT protocol

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patients with myeloma/related diseases<br> | Other: No drugs are involved<br>* No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.<br>* Other names: none, no treatment;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Thereapeutic Recommendantion for Children With a Hodgkin Lymphoma

Study Overview
=================
Brief Summary
-----------------
The GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data. Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unites who will adapt these recommendations.

Detailed Description
-----------------
In high-income countries, therapeutic outcomes exceed 90% and therapeutic de-escalation is necessary to reduce mainly the effects of long-term radiotherapy. Within the same country, there are also differences between the therapeutic protocols used in the different centres. The Experience of Sub-Saharan African Units of the Franco-African Paediatric Oncology Group (GFAOP) in the treatment of pediatric Hodgkin lymphoma in 104 patients was based on chemotherapy alone. The latter was based on COPP/ABV cures without complementary irradiation adapted to the initial stratification and modulated according to the morphological response. Overall survival at 5 years was 82% at 30 months after a median decrease of 17 months. It seemed appropriate to bring together in a single committee the representatives of the various pilot units in order to standardize the therapeutic protocols in the African countries. So with this recommendation the GFAOP propose a simple and reproducible staging according to clinical, biological and radiological data. - Develop standardized but different therapeutic recommendations based on the availability or lack of radiation therapy in the pilot unit.

Official Title
-----------------
Therapeutic Recommendations for Children Registered in the RFAOP Register and With a Hodgkin Lymphoma

Conditions
-----------------
Staging, Therapeutic Recommendations

Intervention / Treatment
-----------------
* Other: Observational


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: under 18 years of age at diagnosis suffering from classical Hodgkin's disease according to the WHO classification. with no history of hematological malignancies or constitutional or acquired immune deficiencies Exclusion Criteria: Over 18 years of age at diagnosis A history of hematological malignancies or a history of constitutional or a history of acquired immune deficiencies

Ages Eligible for Study
-----------------
Minimum Age: 0 Months
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Observational|Descriptive data will be collected to evaluation compliance with the protocol and to evaluate outcome|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patient status | Dead or Alive | 24 months | 
| Drugs | The evaluation of the number of children who remain untreated because of lack of acess to chemotherapy | 24 months |
Epidemiology of Infections in Pediatric Cancer Patients

Study Overview
=================
Brief Summary
-----------------
Infections are common causes of morbidity and mortality in pediatric cancer patients. Today, there are limited data on the incidence, distribution of specific infections, causative agents and risk factors for severe infections in this population. Moreover, little data exist on the epidemiology of infections among pediatric patients with solid tumors. The objectives of the present study are to define the incidence, categories of infections by organ systems, etiologic agents and risk factors for infections in different pediatric malignancies. The results of this study will help the investigators to better understand the epidemiology of infections in the different types of pediatric malignancies, enable the investigators to identify high risk patients, and design a better approach to empiric treatment of these patients. A prospective, multi-center study, conducted in 5 pediatric hematology-oncology units across Israel (Rambam Medical Center, Haemek Medical Center, Schneider Children's Medical Center, Hadassah Medical Center, Soroka Medical Center). All children aged 0-18 years of age, newly diagnosed with cancer and admitted to day care or inpatient departments with fever of >38.0 C will be included in the study. Demographic, clinical and microbiological figures will be collected in each center by a research assistant supervised by the infectious disease specialist. Data will be collected according to a pre-defined Patient Data Form and entered into an electronic data base that will be analyzed accordingly. In each event of febrile episode during chemotherapy, the following data will be collected by a research assistant using a patient data form and computerized software: Demographic data: age, gender, ethnicity. Clinical data: Underlying disease, immunizations, prophylactic antibiotics, presence of central venous catheter, intensity of chemotherapy, duration of fever, duration and severity of neutropenia, diagnosis of present event. Imaging data Microbiological data Outcome The statistical analysis will be performed by an epidemiologist and statistician using the SPSS 12.0 software.

Official Title
-----------------
Epidemiology of Infections in Pediatric Cancer Patients: A Prospective Multicenter Study in Israel

Conditions
-----------------
Infections

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pediatric cancer patients admitted to hospital with fever

Ages Eligible for Study
-----------------
Maximum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
To define the incidence, categories of infections by organ systems, etiologic agents and risk
Correlation Between Colposcopist Findings and Digital Cervicography Employing Gynescope System

Study Overview
=================
Brief Summary
-----------------
Correlation between colposcopist findings and digital cervicography employing Gynescope system

Detailed Description
-----------------
Up to 30 women that will be referred for colposcopy examination at the standard indications will also undergo a colposcopy examination of the cervix by a gynescope. The physicain performing the optical test will record the findings in accordance with the International Federation for Cervical Pathology and Colposcopy (IFCPC) terminology. Categorical variable will be included in every record. At later stage, the images obtained by the cervicography will be evaluated and recorded in accordance with the IFCPC terminology. Correlation between the categorical findings in both assesments will be compared. The correlation measure will be performed by Kappa test according to the categorial result of both measurements.

Official Title
-----------------
Correlation Between Colposcopist Findings and Digital Cervicography Employing Gynescope System

Conditions
-----------------
Cervical Dysplasia

Intervention / Treatment
-----------------
* Diagnostic Test: Digital cervicography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients reffered for colposcopy Exclusion Criteria: Patient refusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Diagnostic Test: Digital cervicography|Colposcopist findings and digital cervicography employing Gynescope system|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Categorical findings according in accordance with the International Federation of Cervical Pathology Colposcopy | leukoplakia, aceto - white change, mosaic, punctuation, and abnormal vessels | 5 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
digital cervicography, Gynescope system
The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage Anastomotic Leakage

Study Overview
=================
Brief Summary
-----------------
Anastomotic leakage (AL) is considered the commonest major complication after surgery for rectal cancer. Transanal tube drainage role in the prevention of AL is still debatable.

Detailed Description
-----------------
Patients who underwent low or ultralow anterior resection for rectal cancer were enrolled between 01/2015 and 06/2017. A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant. Patients were followed-up on the ward and then in the outpatient's department at two weeks, and one month postoperative. Patients who were suspected to have AL underwent CT with rectal contrast to assess the integrity of the anastomosis. The primary outcome was the incidence of AL. We adopted the definition published by the International Study Group of Rectal Cancer.

Official Title
-----------------
The Role of Transanal Tube Drainage as A Mean of Prevention of Anastomotic Leakage

Conditions
-----------------
Rectal Cancer, Rectal Neoplasms, Anastomotic Leak

Intervention / Treatment
-----------------
* Other: Tube drain insertion


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Low or ultralow anterior resection with primary anastomosis for biopsy-proven primary rectal cancer Exclusion Criteria: No anastomosis
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: TD<br> | Other: Tube drain insertion<br>* A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.<br>|
| No Intervention: NTD<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anastomotic leakage | Prevention | 30 days |
Functional Outcome After Cardiac Arrest

Study Overview
=================
Brief Summary
-----------------
Descriptive and prognosis study of the functional outcome after cardiac arrest for the patients awake within the first 15 days.

Detailed Description
-----------------
Functional outcome after cerebral anoxia due to cardiac arrest is poorly documented.. Survival after out of hospital cardiac arrest has improved and long term follow up of the patients is not routinely effective. Patients showing sign of awakening very early are considered in a good outcome group. Nevertheless they can experience some restriction and difficulties when they try to return to their premorbid level of functioning. We aim to study their long term functional outcome and their level of anxiety, depression, quality of life and caregiver burden as well as their general cognitive functioning. Prognosis factors will be studied in the acute phase.

Official Title
-----------------
Functional Outcome After Cardiac Arrest; Prediction and Prognosis Factors for Patients Awake Within the First 15 Days

Conditions
-----------------
Out of Hospital Cardiac Arrest

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria : age 18 to 85 Out of hospital cardiac arrest ; cardiac arrest in the ER is eligible Glasgow Coma Score ≥ 12 within 15 days after onset Living in the parisian area Exclusion criteria : no social security Neurological condition (multiple sclerosis, parkinson disease, AMS, stroke) priori to the cardiac arrest Psychiatric condition (schizophrenia, severe bipolar syndrome, long term neuroleptic medication, autistic spectrum disorders Deafness and blindness Neoplasia Premorbid limitation of autonomy. Difficulties in speaking and writing the French language

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glasgow outcome Scale Extended score | Functional outcome at 18 months | 18 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral anoxia, Functional outcome
A Randomized Study Evaluating the Feasibility and Activity of Three Different Combination With Gemcitabine as First Line Therapy for Non Small Cell Lung Cancer

Study Overview
=================
Brief Summary
-----------------
Phase II study that will evaluate the activity of gemcitabine as intravesical therapy on the marker lesion in superficial bladder carcinoma at intermediate risk. Primary objective is the evaluation of the pathological complete response after 8 instillation of gemcitabine. 46 patients are requested.

Official Title
-----------------
A Multicenter Randomized Phase II Study Evaluating the Feasibility and Activity of Two Different Combinations of Docetaxel (RP56976, TAXOTERE *) and Gemcitabine and of Cisplatin/Gemcitabine Followed by Docetaxel as First Line Therapy for Locally Advanced Unresectable or Metastatic Non Small Cell Lung Cancer

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung

Intervention / Treatment
-----------------
* Drug: Gemcitabine
* Drug: docetaxel
* Drug: cisplatin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria Histologically or cytologically confirmed diagnosis of NSCLC Patients must have a locoregionally advanced unresectable non metastatic NSCLC Stage IIIB (only N3 supraclavicular or T4 for pleural effusion) or Stage IV according to the revised International Staging System Patients must have at least one measurable lesion WHO Performance Status 0 or 1 Adequate Organ Function Exclusion criteria: Prior systemic chemotherapy or immunotherapy including neoadjuvant or adjuvant treatments Prior radiotherapy for NSCLC Patients with symptomatic brain metastases or with leptomeningeal disease. However, patients with symptomatic brain metastases who become asymptomatic under corticosteroids treatment can enter the study Current peripheral neuropathy NCI grade 2

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Gemcitabine|nan|
|Drug: docetaxel|nan|
|Drug: cisplatin|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the antitumour activity as measured by response rate in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) of two different combinations of docetaxel and gemcitabine and of a sequential treatment of |  |  | 
| cisplatin /gemcitabine |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To determine time to progression, duration of response, time to treatment failure, and overall survival in each group. |  |  | 
| To evaluate changes from baseline in the Lung Cancer Symptom Scale of patients in each treatment arm |  |  |
Students' View: Survey of Medical Education in Taiwan

Study Overview
=================
Brief Summary
-----------------
The aim of this research project is to establish a students' perspective to most medical schools in Taiwan. We expect that these surveys will provide helpful information to candidates for selection of medical school before admission, and will also be a useful reference guide to improve quality of medical education to our governmental policy makers.

Detailed Description
-----------------
The aim of this research project is to establish a students' perspective to most medical schools in Taiwan. We will select Medical School Graduation Questionnaires, obtained from Association of American Medical Colleges, AAMC, which has been performed in US for more than 30 years. These questionnaires will modify with edition with expert opinions of our country. We will invite students' representative of each school for survey visit and deliver questionnaires to students after complete communication and permission of their schools. These surveys include learning resources, student support services, student daily life, medical education…etc. We expect that these surveys will provide helpful information to candidates for selection of medical school before admission, and will also be a useful reference guide to improve quality of medical education to our governmental policy makers.

Official Title
-----------------
Students' View: Survey of Medical Education in Taiwan

Conditions
-----------------
Understand Students' View Toward Current Medical Education.

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: medical students at their graduate year and are willing to fill out the questionnaire. Exclusion Criteria: medical students who do not want to fill out the questionnaire.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| medical students, graduate year,<br>medical students at graduate year will be invited to participate in this study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Filled out the assigned questionnaire. |  | 1 month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
questionnaire, medical education, medical students.